297 related articles for article (PubMed ID: 35211122)
1. The Predictive Potential of the Baseline C-Reactive Protein Levels for the Efficiency of Immune Checkpoint Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis.
Han CL; Meng GX; Ding ZN; Dong ZR; Chen ZQ; Hong JG; Yan LJ; Liu H; Tian BW; Yang LS; Xue JS; Li T
Front Immunol; 2022; 13():827788. PubMed ID: 35211122
[TBL] [Abstract][Full Text] [Related]
2. Outcomes Following Immune Checkpoint Inhibitor Treatment of Patients With Microsatellite Instability-High Cancers: A Systematic Review and Meta-analysis.
Petrelli F; Ghidini M; Ghidini A; Tomasello G
JAMA Oncol; 2020 Jul; 6(7):1068-1071. PubMed ID: 32407439
[TBL] [Abstract][Full Text] [Related]
3. Peripheral cytokine levels as novel predictors of survival in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis.
Mao XC; Yang CC; Yang YF; Yan LJ; Ding ZN; Liu H; Yan YC; Dong ZR; Wang DX; Li T
Front Immunol; 2022; 13():884592. PubMed ID: 36072577
[TBL] [Abstract][Full Text] [Related]
4. Baseline C-reactive protein predicts efficacy of the first-line immune checkpoint inhibitors plus chemotherapy in advanced lung squamous cell carcinoma: a retrospective, multicenter study.
Zheng X; Zhang L; Wu L; Zhao J; Sun J; Fang Y; Zhou J; Chu Q; Shen Y; Yang Z; Chen L; Huang M; Lin X; Liu Z; Shen P; Wang Z; Wang X; Wang H; Han Z; Liu A; Zhang H; Ye F; Gao W; Wu F; Song Z; Chen S; Zhou C; Wang Q; Xu C; Huang D; Zheng X; Miao Q; Jiang K; Xu Y; Wu S; Wang H; Zhang Q; Yang S; Li Y; Chen S; Lin G
BMC Cancer; 2023 Dec; 23(1):1244. PubMed ID: 38104105
[TBL] [Abstract][Full Text] [Related]
5. Modified Glasgow Prognostic Score associated with survival in metastatic renal cell carcinoma treated with immune checkpoint inhibitors.
Brown JT; Liu Y; Shabto JM; Martini D; Ravindranathan D; Hitron EE; Russler GA; Caulfield S; Yantorni L; Joshi SS; Kissick H; Ogan K; Nazha B; Carthon BC; Kucuk O; Harris WB; Master VA; Bilen MA
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34326170
[TBL] [Abstract][Full Text] [Related]
6. C-reactive protein is a predictor of prognosis in renal cell carcinoma patients receiving tyrosine kinase inhibitors: A meta-analysis.
Wang Z; Peng S; Wang A; Xie H; Guo L; Jiang N; Niu Y
Clin Chim Acta; 2017 Dec; 475():178-187. PubMed ID: 29080691
[TBL] [Abstract][Full Text] [Related]
7. Association between baseline C‑reactive protein level and survival outcomes for cancer patients treated with immunotherapy: A meta‑analysis.
Xu Y; Ma K; Zhang F; Ma M; Hong L; Wang J; Li S; Sun P; Wang J; Wei S
Exp Ther Med; 2023 Aug; 26(2):361. PubMed ID: 37408861
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of programmed cell death-ligand 1 expression on circulating tumor cells in various cancers: A systematic review and meta-analysis.
Ouyang Y; Liu W; Zhang N; Yang X; Li J; Long S
Cancer Med; 2021 Oct; 10(20):7021-7039. PubMed ID: 34423578
[TBL] [Abstract][Full Text] [Related]
9. Corticosteroid administration for cancer-related indications is an unfavorable prognostic factor in solid cancer patients receiving immune checkpoint inhibitor treatment.
Wang Y; Yang M; Tao M; Liu P; Kong C; Li H; Chen Y; Yin X; Yan X
Int Immunopharmacol; 2021 Oct; 99():108031. PubMed ID: 34358857
[TBL] [Abstract][Full Text] [Related]
10. Early kinetics of C reactive protein for cancer-agnostic prediction of therapy response and mortality in patients treated with immune checkpoint inhibitors: a multicenter cohort study.
Barth DA; Moik F; Steinlechner S; Posch F; Mayer MC; Sandner AM; Berton F; Schlintl V; Koch L; John N; Wurm R; Pichler M; Bauernhofer T; Reimann P; Wohlkönig C; Richtig E; Winder T; Preusser M; Jost PJ; Ay C; Gerger A; Terbuch A; Riedl JM
J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38097343
[TBL] [Abstract][Full Text] [Related]
11. Neutrophil-to-Lymphocyte Ratio as a Prognostic Biomarker for Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
Chen X; Meng F; Jiang R
Front Oncol; 2021; 11():746976. PubMed ID: 34900692
[TBL] [Abstract][Full Text] [Related]
12. Focus on the Dynamics of Neutrophil-to-Lymphocyte Ratio in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Meta-Analysis and Systematic Review.
Guo Y; Xiang D; Wan J; Yang L; Zheng C
Cancers (Basel); 2022 Oct; 14(21):. PubMed ID: 36358716
[TBL] [Abstract][Full Text] [Related]
13. Predictive value of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis.
Zhang N; Jiang J; Tang S; Sun G
Int Immunopharmacol; 2020 Aug; 85():106677. PubMed ID: 32531712
[TBL] [Abstract][Full Text] [Related]
14. Blood biomarkers predict outcomes in patients with hepatocellular carcinoma treated with immune checkpoint Inhibitors: A pooled analysis of 44 retrospective sudies.
Zhang L; Feng J; Kuang T; Chai D; Qiu Z; Deng W; Dong K; Zhao K; Wang W
Int Immunopharmacol; 2023 May; 118():110019. PubMed ID: 36933492
[TBL] [Abstract][Full Text] [Related]
15. Anti-PD-1/L1-associated immune-related adverse events as harbinger of favorable clinical outcome: systematic review and meta-analysis.
Park R; Lopes L; Saeed A
Clin Transl Oncol; 2021 Jan; 23(1):100-109. PubMed ID: 32495269
[TBL] [Abstract][Full Text] [Related]
16. Cutaneous Adverse Events and Cancer Survival Prognosis With Immune Checkpoint Inhibitor Treatment: A Systematic Review and Meta-Analysis.
Du Y; Wu W; Chen M; Dong Z; Wang F
JAMA Dermatol; 2023 Oct; 159(10):1093-1101. PubMed ID: 37672255
[TBL] [Abstract][Full Text] [Related]
17. An Up-To-Date Investigation Into the Correlation Between Proton Pump Inhibitor Use and the Clinical Efficacy of Immune Checkpoint Inhibitors in Advanced Solid Cancers: A Systematic Review and Meta-Analysis.
Liu C; Guo H; Mao H; Tong J; Yang M; Yan X
Front Oncol; 2022; 12():753234. PubMed ID: 35280736
[TBL] [Abstract][Full Text] [Related]
18. The predictive value of tumor mutation burden on survival of gastric cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis.
Ke L; Li S; Huang D
Int Immunopharmacol; 2023 Nov; 124(Pt B):110986. PubMed ID: 37748223
[TBL] [Abstract][Full Text] [Related]
19. Prospective development and validation of a liquid immune profile-based signature (LIPS) to predict response of patients with recurrent/metastatic cancer to immune checkpoint inhibitors.
Zhou JG; Donaubauer AJ; Frey B; Becker I; Rutzner S; Eckstein M; Sun R; Ma H; Schubert P; Schweizer C; Fietkau R; Deutsch E; Gaipl U; Hecht M
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33593828
[TBL] [Abstract][Full Text] [Related]
20. Association between pretreatment C-reactive protein level and survival in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis.
Wang H; Yang R; Zhou K; Wang S; Cheng C; Liu D; Li W
Int Immunopharmacol; 2023 Nov; 124(Pt B):110937. PubMed ID: 37757636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
